USD 1.08 Billion growth opportunity in Foot and Mouth Disease Vaccines Market | Asia to occupy 63% market share | Technavio
NEW YORK, July 6, 2022 /PRNewswire/ -- The "Foot and Mouth Disease Vaccines Market by Product and Geography - Forecast and Analysis 2021-2025" report by Technavio expects the market size to increase by USD 1.08 billion between 2020 and 2025. The market observed a YOY growth of 8.50% and the growth momentum is expected to accelerate at a CAGR of 8.81% during the forecast period. According to the report, the Asian market will generate huge growth opportunities for vendors. The widespread awareness programs are undertaken by governments and the implementation of needle and syringe exchange programs in Australia, New Zealand, and Malaysia are driving the demand for foot and mouth disease vaccines in the region.
Get more insights into the current market scenario, future growth opportunities, and other important statistics. Read Our Sample Report Now
Market Dynamics
The market is mainly driven by the increase in government initiatives. Governments across the world are undertaking various initiatives to eradicate FMD. For instance, the US Congress passed a Farm Bill in December 2018 to provide funding for an animal vaccine bank emphasizing the development of FMD vaccines. Similarly, in India, the Prayagraj animal husbandry department in Uttar Pradesh state launched a massive drive to treat cows and other cattle from the deadly foot and mouth disease. Such initiatives are creating a high demand for FMD vaccines across the globe.
In addition, frequent foot and mouth disease (FMD) outbreaks in Asia and the Middle East and the increase in demand for livestock products will have a positive impact on the growth of the market. However, the increase in vaccine failures is expected to hinder the growth of the market.
Competitive Analysis
Some of the companies covered in this report are Biogenesis Bago SA, Boehringer Ingelheim International GmbH, Ceva Sante Animale, Indian Immunologicals Ltd., Inovio Pharmaceuticals Inc., LIMOR DE COLOMBIA SA, Merck & Co. Inc., SEPPIC SA, VECOL SA, and VETAL Animal Health Products Inc., etc. The competitive scenario provided in the foot and mouth disease vaccines market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.
The market is concentrated. Vendors in the market are focusing on implementing new technologies and new product offerings. They are adopting various strategies to increase their market shares and remain competitive in the market. Some of the major strategies adopted by them include product launches, M&A, distribution through partnerships, participation in medical trade shows, and product development through the use of advanced technologies.
View Sample Report to gain more insights into the market dynamics and the vendor landscape.
Market Segmentation by Product:
- By product, the market is classified into conventional vaccines and emergency vaccines.
- The market growth in the conventional vaccines segment will be significant during the forecast period.
- The segment is driven by the presence of FMD endemic in various countries such as India, China, Bangladesh, South Korea, Pakistan, and Hong Kong.
Market Segmentation by Product:
- By geography, the market is classified as Asia, Europe, North America, and ROW.
- Asia will have the largest share of the market.
- The presence of a large patient pool and developing veterinary infrastructure are driving the regional market's growth.
Related Reports:
- Infectious Disease Diagnostics Market by End-user and Geography - Forecast and Analysis 2022-2026
- Vaccine Research Market by End-user and Geography - Forecast and Analysis 2022-2026
Foot And Mouth Disease Vaccines Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 8.81% |
Market growth 2021-2025 |
USD 1.08 billion |
Market structure |
Concentrated |
YoY growth (%) |
8.50 |
Regional analysis |
Asia, Europe, North America, and ROW |
Performing market contribution |
Asia at 63% |
Key consumer countries |
China, South Korea (Republic of Korea), South Africa, Iran (Islamic Republic of Iran), and India |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Biogenesis Bago SA, Boehringer Ingelheim International GmbH, Ceva Sante Animale, Indian Immunologicals Ltd., Inovio Pharmaceuticals Inc., LIMOR DE COLOMBIA SA , Merck & Co. Inc., SEPPIC SA, VECOL SA, and VETAL Animal Health Products Inc. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Contents:
1 Executive Summary
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 01: Parent market
- Exhibit 02: Market characteristics
- 2.2 Value chain analysis
- Exhibit 03: Value Chain Analysis: Pharmaceuticals
3 Market Sizing
- 3.1 Market definition
- Exhibit 04: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 05: Market segments
- 3.3 Market size 2020
- 3.4 Market outlook: Forecast for 2020 - 2025
- Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)
- Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)
4 Five Forces Analysis
- 4.1 Five Forces Summary
- Exhibit 08: Five forces analysis 2020 & 2025
- 4.2 Bargaining power of buyers
- Exhibit 09: Bargaining power of buyers
- 4.3 Bargaining power of suppliers
- Exhibit 10: Bargaining power of suppliers
- 4.4 Threat of new entrants
- Exhibit 11: Threat of new entrants
- 4.5 Threat of substitutes
- Exhibit 12: Threat of substitutes
- 4.6 Threat of rivalry
- Exhibit 13: Threat of rivalry
- 4.7 Market condition
- Exhibit 14: Market condition - Five forces 2020
5 Market Segmentation by Product
- 5.1 Market segments
- Exhibit 15: Product - Market share 2020-2025 (%)
- 5.2 Comparison by Product
- Exhibit 16: Comparison by Product
- 5.3 Conventional vaccines - Market size and forecast 2020-2025
- Exhibit 17: Conventional vaccines - Market size and forecast 2020-2025 ($ million)
- Exhibit 18: Conventional vaccines - Year-over-year growth 2020-2025 (%)
- 5.4 Emergency vaccines - Market size and forecast 2020-2025
- Exhibit 19: Emergency vaccines - Market size and forecast 2020-2025 ($ million)
- Exhibit 20: Emergency vaccines - Year-over-year growth 2020-2025 (%)
- 5.5 Market opportunity by Product
- Exhibit 21: Market opportunity by Product
6 Customer Landscape
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 23: Market share by geography 2020-2025 (%)
- 7.2 Geographic comparison
- Exhibit 24: Geographic comparison
- 7.3 Asia - Market size and forecast 2020-2025
- Exhibit 25: Asia - Market size and forecast 2020-2025 ($ million)
- Exhibit 26: Asia - Year-over-year growth 2020-2025 (%)
- 7.4 Europe - Market size and forecast 2020-2025
- Exhibit 27: Europe - Market size and forecast 2020-2025 ($ million)
- Exhibit 28: Europe - Year-over-year growth 2020-2025 (%)
- 7.5 North America - Market size and forecast 2020-2025
- Exhibit 29: North America - Market size and forecast 2020-2025 ($ million)
- Exhibit 30: North America - Year-over-year growth 2020-2025 (%)
- 7.6 ROW - Market size and forecast 2020-2025
- Exhibit 31: ROW - Market size and forecast 2020-2025 ($ million)
- Exhibit 32: ROW - Year-over-year growth 2020-2025 (%)
- 7.7 Key leading countries
- Exhibit 33: Key leading countries
- 7.8 Market opportunity by geography
- Exhibit 34: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.1 Market drivers
- 8.2 Market challenges
- Exhibit 35: Impact of drivers and challenges
- 8.3 Market trends
9 Vendor Landscape
- 9.1 Overview
- 9.2 Vendor landscape
- Exhibit 36: Vendor landscape
- 9.3 Landscape disruption
- Exhibit 37: Landscape disruption
- Exhibit 38: Industry risks
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 39: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 40: Market positioning of vendors
- 10.3 Biogenesis Bago SA
- Exhibit 41: Biogenesis Bago SA - Overview
- Exhibit 42: Biogenesis Bago SA - Product and service
- Exhibit 43: Biogenesis Bago SA - Key news
- Exhibit 44: Biogenesis Bago SA - Key offerings
- 10.4 Boehringer Ingelheim International GmbH
- Exhibit 45: Boehringer Ingelheim International GmbH - Overview
- Exhibit 46: Boehringer Ingelheim International GmbH - Business segments
- Exhibit 47: Boehringer Ingelheim International GmbH - Key news
- Exhibit 48: Boehringer Ingelheim International GmbH - Key offerings
- Exhibit 49: Boehringer Ingelheim International GmbH - Segment focus
- 10.5 Ceva Sante Animale
- Exhibit 50: Ceva Sante Animale - Overview
- Exhibit 51: Ceva Sante Animale - Product and service
- Exhibit 52: Ceva Sante Animale - Key offerings
- 10.6 Indian Immunologicals Ltd.
- Exhibit 53: Indian Immunologicals Ltd. - Overview
- Exhibit 54: Indian Immunologicals Ltd. - Product and service
- Exhibit 55: Indian Immunologicals Ltd. - Key offerings
- 10.7 Inovio Pharmaceuticals Inc.
- 10.8 LIMOR DE COLOMBIA SA
- Exhibit 60: LIMOR DE COLOMBIA SA - Overview
- Exhibit 61: LIMOR DE COLOMBIA SA - Product and service
- Exhibit 62: LIMOR DE COLOMBIA SA - Key offerings
- 10.9 Merck & Co. Inc.
- Exhibit 63: Merck & Co. Inc. - Overview
- Exhibit 64: Merck & Co. Inc. - Business segments
- Exhibit 65: Merck & Co. Inc. - Key offerings
- Exhibit 66: Merck & Co. Inc. - Segment focus
- 10.10 SEPPIC SA
- Exhibit 67: SEPPIC SA - Overview
- Exhibit 68: SEPPIC SA - Product and service
- Exhibit 69: SEPPIC SA - Key offerings
- 10.11 VECOL SA
- Exhibit 70: VECOL SA - Overview
- Exhibit 71: VECOL SA - Product and service
- Exhibit 72: VECOL SA - Key offerings
- 10.12 VETAL Animal Health Products Inc.
- Exhibit 73: VETAL Animal Health Products Inc. - Overview
- Exhibit 74: VETAL Animal Health Products Inc. - Product and service
- Exhibit 75: VETAL Animal Health Products Inc. - Key offerings
11 Appendix
- 11.1 Scope of the report
- 11.2 Currency conversion rates for US$
- Exhibit 76: Currency conversion rates for US$
- 11.3 Research methodology
- Exhibit 77: Research Methodology
- Exhibit 78: Validation techniques employed for market sizing
- Exhibit 79: Information sources
- 11.4 List of abbreviations
- Exhibit 80: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Infiniti Research, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article